Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery-Reference-Cited by-同舟云学术

Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery

Published:2024-07-27 Issue: Volume: Page:
ISSN:0962-9343
Container-title:Quality of Life Research
language:en
Short-container-title:Qual Life Res

Author:

Kachnic Lisa A.^ORCID,Winter Kathryn,Suntharalingam Mohan,Ilson David,Konski André,Lloyd Shane,McAvoy Sarah A.,Lad Thomas,Olowokure Olugbenga Gbenga,Samson Pamela,Gore Elizabeth M.,Meyer Joshua E.,Videtic Gregory M. M.,Clump David A.,Raben Adam,Kayaleh Omar,Barker Jerry,Haddock Michael G.,Hopkins Judith O.,Bruner Deborah W.

Funder

National Cancer Institute

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11136-024-03736-7.pdf

Reference28 articles.

1. Jemal, A., Bray, F., Center, M. M., et al. (2011). Global cancer statistics. CA Cancer Journal for Clinicians, 61(2), 69–90.

2. Siegel, R., Ma, J., Zou, Z., et al. (2014). Cancer statistics 2014. CA Cancer Journal for Clinicians, 64(1), 9–29.

3. Herskovic, A., Martz, K., Al-Sarraf, M., et al. (1992). Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New England Journal of Medicine, 326(24), 1593–1598.

4. Cooper, J. S., Guo, M. D., Herskovic, A., et al. (1999). Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA, 281(17), 1623–1627.

5. Minsky, B. D., Pajak, T. F., Ginsberg, R. J., et al. (2002). Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90–12): INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. Journal of Clinical Oncology, 20(5), 1167–1174.